• Home
  • MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.

MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.

Author List
Mathur R, Zhang Y, Grimmer MR, Hong C, Zhang M, Bollam S, Petrecca K, Clarke J, Berger MS, Phillips JJ, Oberheim-Bush NA, Molinaro AM, Chang SM, Costello JF
Publication
Neuro-oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/100941494
Publication Year
2020
PubMed ID
32166314
Publication Title
Mathur R, Zhang Y, Grimmer MR, Hong C, Zhang M, Bollam S, Petrecca K, Clarke J, Berger MS, Phillips JJ, Oberheim-Bush NA, Molinaro AM, Chang SM, Costello JF. MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. Neuro Oncol. 2020 11 26; 22(11):1580-1590.